Spring Bio Solution’s Post

#NCEMinus1Opportunity #alert Watch this video for more information about the NCE minus one opportunity for the molecule #Truqap to treat breast cancer that meets certain disease criteria. If you want to know more about this NCE minus 1 opportunity or want to conduct comprehensive research on the potential of this opportunity, write to us at bd@springbiosolution.com Visit us at https://lnkd.in/dw2U7yCr to learn more about us and our team. Check all the NCE minus 1 videos from 2023 here: https://lnkd.in/gF3Z3Yf5 Nikhila Shashikanth I Vrishali Sekhar I Pramila Coutinho I Vikrant Chudasama I Priyanka Kochrekar I Falak khan I Priyanka Ganeriwal I Shreyas Shendge I Akhilesh Chaudhari I Anuja Pandit | Ingrid Hoyos #SpringBioSolution #SpringBio #NCEMinus1 #NCEMinus1Opportunity #drugdiscovery #drugdevelopment #drugresearch #rlddrugs #genericmedicines #genericdrugs #clinicaltrials #pharma #pharmaindustry #pharmainnovation

#NCEMinus1Opportunity #alert Watch this video for more information about the NCE minus one opportunity for the molecule #Fruzaqla to treat refractory, metastatic colorectal cancer. If you want to know more about this NCE minus 1 opportunity or want to conduct comprehensive research on the potential of this opportunity, write to us at bd@springbiosolution.com Visit us at https://lnkd.in/d8N42BvP to learn more about us and our team. Check all the NCE minus 1 videos from 2023 here: https://lnkd.in/gF3Z3Yf5 Nikhila Shashikanth I Vrishali Sekhar I Pramila Coutinho I Vikrant Chudasama I Priyanka Kochrekar I Falak khan I Priyanka Ganeriwal I Shreyas Shendge I Akhilesh Chaudhari I Anuja Pandit | Ingrid Hoyos #SpringBioSolution #SpringBio #NCEMinus1 #NCEMinus1Opportunity #drugdiscovery #drugdevelopment #drugresearch #rlddrugs #genericmedicines #genericdrugs #clinicaltrials #pharma #pharmaindustry #pharmainnovation

#NCEMinus1Opportunity #alert Watch this video for more information about the NCE minus one opportunity for the molecule #Fruzaqla to treat refractory, metastatic colorectal cancer. If you want to know more about this NCE minus 1 opportunity or want to conduct comprehensive research on the potential of this opportunity, write to us at bd@springbiosolution.com Visit us at https://lnkd.in/d8N42BvP to learn more about us and our team. Check all the NCE minus 1 videos from 2023 here: https://lnkd.in/gF3Z3Yf5 Salim Shaikh Sadiq I Nikhila Shashikanth I Vrishali Sekhar I Pramila Coutinho I Vikrant Chudasama I Priyanka Kochrekar I Falak khan I Priyanka Ganeriwal I Shreyas Shendge I Akhilesh Chaudhari I Anuja Pandit | Ingrid Hoyos #SpringBioSolution #SpringBio #NCEMinus1 #NCEMinus1Opportunity #drugdiscovery #drugdevelopment #drugresearch #rlddrugs #genericmedicines #genericdrugs #clinicaltrials #pharma #pharmaindustry #pharmainnovation

Our “plasma-assisted drug delivery system” is a platform with applications in various clinical indications including #cancers, #autoimmune and #inflammatory #skin conditions and #wounds. Our #focus currently is on head and neck squamous cell #carcinoma – a cancer that is rising in prevalence, #glioblastoma, and #gynaecological cancers. Watch this space for highlights of exciting preliminary results from our academic #collaborators. ------------------------------------------------------------------------------------ #plasmamedicine #coldplasma #plasmajet #materials #plasmahydrogeltherapy #cancertreatment #cancertherapy #plasmaoncology #oncology #braincancer #vulvarcancer #headandneckcancer #starups #startupnews #researchcollaborations #innovators #medtech #ukri #researchandinnovation #plasma4 #lifescience

MedTalks - An interview with Brian Frenzel, CEO of TOSK discussing the company's business and its investment opportunities Tosk has developed and patented two important side-effect-blocking agents, TK-90 for mucositis and pulmonary fibrosis, and TK-39 for cardiotoxicity. Sponsored by NIH SBIR grants, Tosk has also identified oncogenic KRAS-inhibiting drug candidates. These are being developed to treat KRAS-positive malignancies, including 90% of pancreatic, 45% of colon, and 35% of lung cancers. https://wix.to/kTy2wOB #tosk #familyofficeconnector #opportunityspotlight #medicalandpharmainsider #fcglobalstrategies

💜Today marks #RareDiseaseDay, shedding light on the challenges faced by those with uncommon conditions. "Rare cancers remain also rarely studied, and that's why we cannot stop working towards finding more options for the patients." says kishor Bhatia, Lantern Pharma Inc. (Nasdaq: LTRN)'s Chief scientific officer. Lantern Pharma is dedicated to pioneering solutions for patients with rare cancers, starting with our drug candidate, LP-184 and LP-284. Discover how Lantern pharma is leveraging AI for rare cancer treatments at www.lanternpharma.com. #RareCancerAwareness #AdvocacyMatters

Johnson & Johnson Highlights Results from the P-II (SunRISe-4) Trial of TAR-200 Plus Cetrelimab to Treat Muscle-Invasive Bladder Cancer at ESMO 2024 #johnsonandjohnson #tar200 #cetrelimab #muscleinvasivebladdercancer #clinicaltrial #phase2 #sunrise4

Ultimovacs ASA Provides Update on the P-II (FOCUS) Study of UV1 Plus Keytruda to Treat Metastatic or Recurrent Head and Neck Cancer #ultimovacs #uv1 #keytruda #headandneckcancer #clinicaltrial #phase2 #focus #metastatic #recurrent #ovariancancer #dovacc #hnscc

📢 Excited to share our new study w/Genentech on how #offlabel drugs are used in 165K #cancer patients https://lnkd.in/gsgaeSrk Takeaways👇: *19% of patients receive off-label cancer drugs (4% for off-guideline); tend to be younger or at academic sites *we IDed mutations predicting treatment outcome *immunotherapies often used before FDA approval *we also built a #transformer to predict when patients receive off-guideline treatments. Much more in our paper! #realworldevidence #cancertreatment #machinelearning Fantastic job by Ruishan Liu, Lisa Wang, Shemra Rizzo, Navdeep Pal, Marius Garmhausen, Sarah Waliany, Sarah McGough, PhD, Yvonne Lin, Zhi Huang, Joel Neal and Ryan Copping 👏👏

𝐅𝐃𝐀 𝐀𝐜𝐜𝐞𝐩𝐭𝐬 𝐏𝐌𝐀 𝐀𝐩𝐩𝐥𝐢𝐜𝐚𝐭𝐢𝐨𝐧 𝐟𝐨𝐫 𝐍𝐨𝐯𝐨𝐜𝐮𝐫𝐞'𝐬 𝐓𝐓𝐅𝐢𝐞𝐥𝐝𝐬 𝐓𝐡𝐞𝐫𝐚𝐩𝐲 𝐢𝐧 𝐍𝐒𝐂𝐋𝐂 The FDA has officially accepted Novocure's Novocure Premarket Approval (PMA) application for the use of Tumor Treating Fields (TTFields) therapy alongside standard systemic therapies in non-small cell lung cancer (NSCLC). This application follows progression on or after platinum-based therapy. Asaf Danziger Asaf Danziger, Novocure’s Chief Executive Officer, stated, “The FDA's acceptance of our PMA application for NSCLC is a significant milestone. We appreciate the efforts of our investigators, patients, and colleagues.” 📅 Key Dates: PMA Application Submission: December 15, 2023 Expected FDA Decision: Second half of 2024 Stay tuned for further developments on this regulatory process. #FDAApproval #NSCLC #MedicalInnovation #Healthcare #LUNARStudy #CancerTherapy #lungcancer